Stoke Therapeutics (NASDAQ: STOK) — Perfil da empresa, notícias e dados financeiros
Stoke Therapeutics focuses on transformative RNA-based therapies for severe genetic diseases, dedicated to pioneering new solutions.
Stoke Therapeutics
Stoke Therapeutics (NASDAQ:STOK) is a biotechnology company focused on addressing the underlying causes of severe genetic diseases by upregulating protein expression with its proprietary RNA-based approach, TANGO (Targeted Augmentation of Nuclear Gene Output). The company aims to pioneer transformative therapies to improve the lives of individuals suffering from diseases caused by a single genetic mutation, such as Dravet syndrome, a severe form of epilepsy. Stoke Therapeutics is dedicated to advancing its lead candidate, STK-001, through clinical development for the treatment of Dravet syndrome, as well as expanding its pipeline to address other genetic conditions. The company's objectives include delivering breakthrough treatments to patients in need and establishing itself as a leader in genetic medicine by leveraging its TANGO technology to address currently untreatable conditions.
Resumo
Operações
Produtos e/ou serviços de Stoke Therapeutics
- STK-001, a treatment targeting Dravet syndrome, aiming to address the underlying cause of this severe form of epilepsy.
- STK-002 focuses on addressing the genetic cause of autosomal dominant optic atrophy.
- Research into TANGO (Targeted Augmentation of Nuclear Gene Output) technology for correcting protein imbalances in genetic diseases.
- Development of therapies for amyotrophic lateral sclerosis (ALS) through genetic modulation.
- Initiatives in creating treatments for Rett Syndrome, emphasizing advancements in neurological disorder therapies.
- Pursuit of novel strategies in combating genetic forms of epilepsy, leveraging cutting-edge RNA editing techniques.
equipe executiva do Stoke Therapeutics
- Ian F. SmithCEO & Director
- Adrian R. KrainerCo-Founder & Independent Director
- Thomas Edward LeggettChief Financial Officer
- Jason HoittChief Patient Officer
- Isabel AznarezCo-Founder & CTO
- Thomas McCauleyChief Scientific Officer
- Jonathan AllanCorporate Secretary, Compliance Officer & General Counsel
- Susan WillsonVice President of Corporate Communications
- Sara Den BestenChief People Officer
- Barry S. TichoChief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Stoke Therapeutics, em USD.
- Cap. de mercado
- 1,7 bi
- Receita (TTM)
- 27,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 184,4 mi | -20,6 mi | -6,9 mi | |
| 36,6 mi | -101,4 mi | -89 mi | |
| 8,8 mi | -114,8 mi | -104,7 mi | |
| 12,4 mi | -104,4 mi | -93,1 mi |